tldrdailynews.com logo
Tag

Alopecia Areata

All articles tagged with #alopecia areata

Rheumatoid arthritis drug shows promise for regrowing hair in alopecia areata
health4 days ago

Rheumatoid arthritis drug shows promise for regrowing hair in alopecia areata

A phase 3 trial found that the JAK inhibitor upadacitinib, used to treat rheumatoid arthritis, regrew hair in about half to just over half of participants with severe alopecia areata within 24 weeks, with 80% scalp coverage achievable at the 30 mg dose. Eyebrows and eyelashes also improved, and participants reported better emotional and social well-being. The drug is approved for severe alopecia areata in Europe and is under FDA review in the U.S.; longer-term safety and durability data are still needed to inform routine use.

via Medical News Today|
#alopecia-areata#hair-regrowth#health
Arthritis drug prompts remarkable hair regrowth in severe alopecia areata, study finds
health8 days ago

Arthritis drug prompts remarkable hair regrowth in severe alopecia areata, study finds

Six-month study shows the arthritis drug upadacitinib (Rinvoq) can trigger dramatic hair regrowth in severe alopecia areata, with 45-55% of patients reaching 80% scalp coverage (more at higher doses) and notable eyebrow/eyelash restoration; the treatment is off-label for alopecia in the US as AbbVie seeks FDA approval, while the EU recently approved it.

via New York Post|
#alopecia-areata#hair-growth#health
Q32’s IL-7R target yields durable alopecia signals, lifting shares
business1 month ago

Q32’s IL-7R target yields durable alopecia signals, lifting shares

Q32 Bio’s phase 2 readout of bempikibart for alopecia areata shows 30.3% SALT-20 and 33.3% SALT-50 responses by 36 weeks (40% in a prespecified modified ITT of 25 patients), with early durability signals after off-drug periods and no treatment-related serious adverse events; the most common adverse event was mild injection-site reactions. The news sparked a roughly 63% intraday stock gain, opening at $18.31 from $11.21. Q32 also announced a registration-directed program for bempikibart in 1H 2027 and continues to market the therapy as a potentially more durable option than JAK inhibitors. The asset is licensed from Bristol Myers Squibb after a prior phase 2 failure in atopic dermatitis, which led the company to shift focus to alopecia areata.

via Fierce Biotech|
#alopecia-areata#bempikibart#business
Nektar's rezpeg shows promising hair regrowth in alopecia, moving toward Phase 3
biotech4 months ago

Nektar's rezpeg shows promising hair regrowth in alopecia, moving toward Phase 3

Nektar Therapeutics reported that extended treatment with its experimental drug rezpeg led to meaningful hair growth in severe alopecia areata after one year, with 27% of participants reaching SALT Score 20 (80%+ scalp coverage). The response is comparable to or better than low-dose Olumiant, though not tested head-to-head, and Nektar plans to begin a Phase 3 trial later this year.

via statnews.com|
#alopecia-areata#biotech#hair-growth
"Proven Methods to Combat Hair Loss: Backed by Science"
health2 years ago

"Proven Methods to Combat Hair Loss: Backed by Science"

Science-backed methods to combat hair loss include platelet-rich plasma (PRP) injections to wake up dormant hair follicles, low-level laser therapy (LLLT) to stimulate hair growth, topical Minoxidil and oral Finasteride to treat pattern baldness, and JAK inhibitors to target alopecia areata, an autoimmune condition causing sudden hair loss. While a cure for baldness remains elusive, advancements in understanding and treating different forms of hair loss offer hope for those seeking to combat this common issue.

via ZME Science|
#alopecia-areata#balding#finasteride
FDA Approves Groundbreaking Hair Loss Drug for Adolescents and Adults
health3 years ago

FDA Approves Groundbreaking Hair Loss Drug for Adolescents and Adults

The FDA has approved LITFULO, a hair loss drug, to treat alopecia areata, an autoimmune disease that causes hair loss on the scalp, face, and body. The drug is approved for adults and adolescents aged 12 and over with severe alopecia areata. The drug inhibits two types of enzymes, blocking inflammatory signaling and cell-killing activity from T cells, which have been implicated in the development of alopecia areata. The clinical trial showed a statistically significant increase in hair coverage for those taking 50 mg of LITFULO compared to placebo.

via Technology Networks|
#alopecia-areata#fda#hair-loss
Toddler diagnosed with alopecia areata due to autoimmune disorder.
health3 years ago

Toddler diagnosed with alopecia areata due to autoimmune disorder.

A 2-year-old girl was diagnosed with alopecia areata, an autoimmune condition that attacks hair follicles, causing bald spots and thinning eyebrows. While there is no cure for alopecia, some treatments are available, including steroid pills, creams, shots, and a new systemic treatment. However, options for children are limited, and some treatments have side effects. Hair regrowth is unpredictable, and some hairs may grow back white at first. Stress is a significant factor in alopecia flare-ups or initiation, and children with eczema have an increased risk of developing alopecia.

via Insider|
#alopecia-areata#autoimmune-condition#childrens-health